8 January 2020 in Nature Communications
STSvetlana S. Tarchevskaya
+4
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.
6 July 2020 in Nature Metabolism
3 December 2021 in Nature Communications
Antibody drugs exert therapeutic effects via a range of mechanisms, including competitive inhibition, allosteric modulation, and immune effector mechanisms. Facilitated dissociation is an additional mechanism where antibody-mediated “disruption” of stable high-affinity macromolecular complexes can potentially enhance therapeutic efficacy. However, this mechanism is not well understood or utilized therapeutically. Here, we investigate and engineer the weak disruptive activity of an existing therapeutic antibody, omalizumab, which targets IgE antibodies to block the allergic response. We develop a yeast display approach to select for and engineer antibody disruptive efficiency and generate potent omalizumab variants that dissociate receptor-bound IgE. We determine a low resolution cryo-EM structure of a transient disruption intermediate containing the IgE-Fc, its partially dissociated receptor and an antibody inhibitor. Our results provide a conceptual framework for engineering disruptive inhibitors for other targets, insights into the failure in clinical trials of the previous high affinity omalizumab HAE variant and anti-IgE antibodies that safely and rapidly disarm allergic effector cells.
22 October 2026 in Clinical & Experimental Allergy
Background: Peanut allergy remains a clinical challenge, with limited treatment options such as omalizumab (Xolair) and allergen immunotherapy (AIT). However, these are constrained by eligibility and safety concerns. AIT induces protective allergen‐neutralizing IgG4 in most, but not all patients. Allergen‐neutralizing IgG4 competes with allergen‐specific IgE, inhibits FcεRI‐mediated mast cell activation, and inhibits IgE‐facilitated antigen presentation via CD23. Recent findings suggest that combining omalizumab with AIT enhances safety and reduces side effects. We hypothesize that controlled allergen exposure combined with peanut‐specific IgG4 mAbs (MY‐4‐mAbs) prevents IgE binding to peanut allergens, reduces CD23‐mediated allergen presentation and Th2 responses, and skews immunity towards protective allergen‐specific IgG while limiting allergen‐specific IgE induction. Methods: PBMCs from peanut‐allergic donors were exposed to Ara h 2 with or without MY‐4‐mAbs. Th2 cytokines, Foxp3+ Tregs, and IgE‐facilitated allergen binding (FAB) to B cells were assessed. In vivo, peanut‐sensitized C3H/HeJ mice underwent oral‐AIT with peanut extract with or without MY‐4‐mAbs and were monitored for anaphylaxis during and after oral‐AIT. Additionally, peanut‐specific IgG and IgE levels were measured before and after oral‐AIT. Results: Ex vivo, MY‐4‐mAbs with Ara h 2 suppressed Th2 cytokines, enhanced IL‐10 secretion, and inhibited FAB. MY‐4‐mAbs redirected allergen binding to myeloid antigen‐presenting cells and promoted tolerance‐associated responses. In vivo, the combination maintained peanut‐specific IgG induced during oral‐AIT, prevented increases in IgE, and reduced mast cell activation. Conclusions: Allergen‐specific IgG4 mAbs with controlled allergen exposure may improve the safety and efficacy of peanut AIT while promoting tolerance‐associated immune responses, which might allow disease modification towards allergen tolerance.